IHH Healthcare is actively seeking a mediated dialogue with Daiichi Sankyo, enlisting its largest shareholder, Mitsui & Co., to bridge communication gaps. This strategic move comes as parallel legal battles persist over a substantial ₹11...
Read More
Sun Pharmaceutical Industries Ltd. will acquire Organon for $11.75 billion in an all-cash deal. Sun Pharma expects $350 million in cost synergies over two to four years, plus sales growth from Organon's innovative, biosimilar, and establ...
Read More
Sun Pharmaceutical Industries Ltd. is financing its $12 billion acquisition of Organon & Co. primarily through a $9.75 billion bank-arranged bridge loan, supplementing $2-$2.5 billion in cash reserves. This move comes as Indian companies...
Read More
Zydus Lifesciences, Torrent Pharmaceuticals, and Ajanta Pharma are driving growth and overcoming industry pressures. Zydus earned crucial USFDA approvals, Torrent launched a dual-formula Semaglutide, and Ajanta Pharma pushes its global s...
Read More
India's Sun Pharmaceutical Industries has agreed to acquire US-based Organon & Co. for $11.75 billion in its largest-ever deal. The transaction, financed by a substantial debt component alongside existing cash reserves, aims to significa...
Read More
Jagsonpal Pharmaceuticals' shareholders approved a Rs 40 crore share buyback at Rs 250 per share. The price is significantly higher than the current stock trading price, sparking questions about capital allocation. The company also faces...
Read More
IKS Health is acquiring TruBridge for $557 million, targeting the U.S. rural hospital EHR and RCM market. The deal promises cross-selling and leverages IKS's turnaround skills. However, it's overshadowed by TruBridge's ongoing securities...
Read More
Despite robotic-assisted joint replacement surgery's clinical advantages, a major insurance coverage gap in India limits patient access. Outdated policy limits and exclusions push patients toward less effective traditional procedures, im...
Read More
Sun Pharmaceutical Industries has agreed to acquire global healthcare company Organon for $11.75 billion in an all-cash deal. This strategic move positions Sun Pharma to become the seventh-largest global player in biosimilars and a top-t...
Read More
Sun Pharmaceutical Industries has acquired Organon for $11.75 billion, the largest deal in Indian pharma history. The market responded positively, with Sun Pharma shares climbing significantly. This strategic move bolsters Sun Pharma's p...
Read More
Cohance Lifesciences Ltd. shares surged 20% to hit the upper circuit Monday after appointing Umang Vohra, former Cipla CEO, as Executive Chairman and Group CEO. The move signals strong growth ambitions in the contract development and man...
Read More
Sun Pharmaceutical Industries Ltd. has agreed to buy Organon for $11.75 billion. The deal is expected to create a combined company with roughly $12.4 billion in revenue, making Sun Pharma a major global player. It aims to be a top three...
Read More
Umang Vohra, credited with transforming Cipla into a specialty pharma leader, is now Chairman and Group CEO at Cohance Lifesciences. He is tasked with shifting the CDMO from volume manufacturing to value-based client partnerships. Invest...
Read More
Sun Pharma announced its largest-ever acquisition, agreeing to buy U.S. firm Organon & Co. for $11.75 billion. This deal propelled benchmark indices Sensex and Nifty nearly 1% higher in early trade. However, analysts caution that geopoli...
Read More
Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, is executing a bold diversification strategy under CEO Adar Poonawalla. Beyond its core mission of producing affordable vaccines, SII is aggressively exp...
Read More
India's Sun Pharmaceutical Industries has agreed to buy U.S.-based Organon & Co. for $11.75 billion in an all-cash deal. This move aims to boost Sun Pharma's global standing to among the top 25 pharmaceutical companies, with combined rev...
Read More
India's top drugmakers are expanding globally. Sun Pharma's $11.75 billion purchase of Organon & Co. is a landmark deal. Zydus Cadila is advancing a malaria drug into Phase III trials, and Alembic Pharmaceuticals received USFDA approval...
Read More
5C Network, an AI-powered teleradiology firm, is bridging India's significant radiologist deficit by integrating its diagnostic platform directly into medical hardware. This strategy aims to bypass slow procurement cycles and bring rapid...
Read More
A national health survey shows a significant rise in reported ailments, particularly chronic conditions, from 7.5% to 13.1%. Despite increased health insurance coverage driven by government schemes, households face escalating medical bil...
Read More
Sun Pharmaceutical Industries is reportedly nearing a $12-13 billion deal to acquire Organon assets. While analysts praise the strategic fit and offer 'buy' ratings, Sun Pharma's stock has dropped nearly 10% in the past month. This marke...
Read More